Comparable stake leader
FMR LLC
SEC ownership of Vaxcyte, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001649094.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Jul 2026
- Public ticker
- PCVX on Nasdaq
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001649094
- Issuer location
- San Carlos, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Vaxcyte, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Jul 2026
13F
13D/G
Lead comparable stake: 14%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
14%
Janus Henderson Group Ltd.
12%
RA CAPITAL MANAGEMENT, L.P.
8.9%
T. Rowe Price Investment Manageme...
8.6%
BlackRock, Inc.
7.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
14%
from 13D/G
|
$1,212,179,482
20,852,907 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
|
12%
|
$1,048,686,999
18,040,375 shares
|
+$85,131,385 | 31 Jul 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
8.9%
|
$801,181,488
12,974,599 shares
|
+$624,169 | 31 Mar 2026 |
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
8.6%
from 13D/G
|
$709,620,000
12,207,450 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.6%
from 13D/G
|
$701,520,339
12,068,129 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$421,416,800
7,252,053 shares
|
$0 | 31 Mar 2026 |
| Jupiter Topco LLC |
13F
Company
|
12%
|
$1,044,355,257
17,965,847 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
4.7%
|
$407,000,973
7,001,565 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$8,921,610.
Buys
$0
Insiders: 0
Sells
$8,921,610
Insiders: 5
Net
-$8,921,610
Shares: -164,776
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 164,776
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 121,873 | $0 | $6,671,917 | -$6,671,917 |
| 3-6 | 0 | 21,537 | $0 | $1,237,830 | -$1,237,830 |
| 6-9 | 0 | 21,366 | $0 | $1,011,863 | -$1,011,863 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Vaxcyte, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Grant Pickering
Net 12M change
-$8,709,258
Latest report
31 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER, Director | $33,725,455 | -$3,634,850 | -9.7% | Median | 31 Aug 2026 |
| Jeff Fairman | VP, Research | $22,935,618 | Mixed | 30 Dec 2022 | ||
| Andrew Guggenhime | President And Cfo | $9,551,979 | -$1,641,716 | -15% | Median | 31 Aug 2026 |
| Jim Wassil | Chief Operating Officer | $8,929,291 | -$1,054,132 | -11% | Median | 31 Aug 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | $4,402,533 | -$1,389,959 | -24% | Median | 31 Aug 2026 |
| Mikhail Eydelman | Svp, Gen Counsel & Corp Sec | $3,012,039 | Filing P/S | 05 Mar 2025 | ||
| Elvia Cowan | SVP, Finance & CAO | $1,696,640 | -$988,601 | -37% | Median | 31 Aug 2026 |
| Halley E. Gilbert | Director | $1,171,058 | Mixed | 15 Jun 2026 | ||
| Heath Lukatch | Director | $1,132,040 | Mixed | 15 Jun 2026 | ||
| Peter Hirth | Director | $1,043,024 | Mixed | 06 Jun 2024 | ||
| Carlos Paya V | Director | $725,270 | Mixed | 15 Jun 2026 | ||
| Anne S. Drapeau | Director | $725,270 | Mixed | 15 Jun 2026 | ||
| Teri Loxam | Director | $725,270 | Mixed | 15 Jun 2026 | ||
| Jacks Lee | Director | $398,402 | Mixed | 15 Jun 2026 | ||
| Michael E. Kamarck | Director | $364,388 | Mixed | 13 Jun 2023 | ||
| John Furey | Director | $308,331 | Mixed | 15 Jun 2026 | ||
| Olivier Brandicourt | Director | $273,058 | Mixed | 15 Jun 2026 | ||
| Jane Wright-Mitchell | General Counsel | $202,438 | Mixed | 16 Aug 2021 | ||
| Patrick J. Heron | Director | Mixed | 02 Jun 2021 | |||
| Paul Sauer | SVP Process Dev, Manufacturing | Mixed | 30 Dec 2022 |
Recent insider transactions for Vaxcyte, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jim Wassil | PCVX | Common Stock | Tax liability | -0.92% | -1,432 | 153,609 | 02 Sep 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Tax liability | -0.76% | -3,427 | 446,958 | 02 Sep 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Tax liability | -1.38% | -1,432 | 102,471 | 02 Sep 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -0.86% | -659 | 75,736 | 02 Sep 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Tax liability | -1.1% | -326 | 29,187 | 02 Sep 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Sale | -2.19% | $212,352 | $61.07 | -3,477 | 155,041 | 01 Sep 2026 | Direct |
| Jim Wassil | PCVX | Common Stock | Options Exercise | 1.44% | 2,250 | 158,518 | 01 Sep 2026 | Direct | ||
| Jim Wassil | PCVX | Stock Option (right to buy) | Options Exercise | -3.27% | -2,250 | 66,648 | 01 Sep 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -0.81% | -1,273 | 156,268 | 31 Aug 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Tax liability | -0.63% | -2,862 | 450,385 | 31 Aug 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Tax liability | -1.21% | -1,273 | 103,903 | 31 Aug 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -0.47% | -361 | 76,395 | 31 Aug 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Tax liability | -0.82% | -243 | 29,513 | 31 Aug 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Sale | -18.1% | $935,068 | $55.00 | -17,000 | 76,756 | 05 Aug 2026 | Direct |
| Harpreet S. Dhaliwal | PCVX | Common Stock | Options Exercise | 22.2% | 17,000 | 93,756 | 05 Aug 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Stock Option (right to buy) | Options Exercise | -37.8% | -17,000 | 28,000 | 05 Aug 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Sale | -1.41% | $121,195 | $53.86 | -2,250 | 157,541 | 03 Aug 2026 | Direct |
| Jim Wassil | PCVX | Common Stock | Options Exercise | 1.43% | 2,250 | 159,791 | 03 Aug 2026 | Direct | ||
| Jim Wassil | PCVX | Stock Option (right to buy) | Options Exercise | -3.16% | -2,250 | 68,898 | 03 Aug 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Sale | -8.68% | $538,879 | $53.89 | -10,000 | 105,176 | 03 Aug 2026 | Direct |
| Andrew Guggenhime | PCVX | Common Stock | Options Exercise | 9.51% | 10,000 | 115,176 | 03 Aug 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Stock Option (right to buy) | Options Exercise | -4.41% | -10,000 | 216,827 | 03 Aug 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Sale | -1.48% | $111,307 | $55.65 | -2,000 | 133,215 | 27 Jul 2026 | By Children's Trust |
| Grant Pickering | PCVX | Common Stock | Sale | -3.45% | $901,069 | $55.63 | -16,198 | 453,247 | 27 Jul 2026 | Direct |
| Grant Pickering | PCVX | Common Stock | Options Exercise | 3.57% | 16,198 | 469,445 | 27 Jul 2026 | Direct | ||
| Grant Pickering | PCVX | Stock Option (right to buy) | Options Exercise | -10.6% | -16,198 | 137,000 | 27 Jul 2026 | Direct | ||
| John Markels | PCVX | Stock Option (right to buy) | Award | 23,029 | 23,029 | 16 Jul 2026 | Direct | |||
| Andrew Guggenhime | PCVX | Common Stock | Sale | -8.74% | $572,837 | $57.28 | -10,000 | 104,395 | 06 Jul 2026 | Direct |
| Andrew Guggenhime | PCVX | Common Stock | Options Exercise | 9.58% | 10,000 | 114,395 | 06 Jul 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Stock Option (right to buy) | Options Exercise | -4.22% | -10,000 | 226,827 | 06 Jul 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Sale | -1.42% | $126,736 | $56.33 | -2,250 | 156,760 | 01 Jul 2026 | Direct |
| Jim Wassil | PCVX | Common Stock | Options Exercise | 0.33% | 516 | 159,010 | 01 Jul 2026 | Direct | ||
| Jim Wassil | PCVX | Stock Option (right to buy) | Options Exercise | -0.72% | -516 | 71,148 | 01 Jul 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Sale | -1.47% | $110,465 | $55.23 | -2,000 | 134,215 | 26 Jun 2026 | By Children's Trust |
| Grant Pickering | PCVX | Common Stock | Sale | -4.68% | $1,227,805 | $55.21 | -22,237 | 452,466 | 26 Jun 2026 | Direct |
| Moncef Slaoui | PCVX | Stock Option (right to buy) | Award | 26,061 | 26,061 | 22 Jun 2026 | Direct | |||
| Grant Pickering | PCVX | Common Stock | Sale | -1.46% | $105,000 | $52.50 | -2,000 | 135,215 | 18 Jun 2026 | By Children's Trust |
| Grant Pickering | PCVX | Common Stock | Sale | -4.52% | $1,179,205 | $52.50 | -22,461 | 474,703 | 18 Jun 2026 | Direct |
| Grant Pickering | PCVX | Common Stock | Options Exercise | 0.05% | 225 | 497,164 | 18 Jun 2026 | Direct | ||
| Grant Pickering | PCVX | Stock Option (right to buy) | Options Exercise | -100% | -225 | 0 | 18 Jun 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Sale | -8.74% | $530,000 | $53.00 | -10,000 | 104,395 | 18 Jun 2026 | Direct |
| Andrew Guggenhime | PCVX | Common Stock | Options Exercise | 9.58% | 10,000 | 114,395 | 18 Jun 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Stock Option (right to buy) | Options Exercise | -4.05% | -10,000 | 236,827 | 18 Jun 2026 | Direct | ||
| Carlos Paya V | PCVX | Common Stock | Award | 49.3% | 2,265 | 6,856 | 15 Jun 2026 | Direct | ||
| Carlos Paya V | PCVX | Stock Option (right to buy) | Award | 11,389 | 11,389 | 15 Jun 2026 | Direct | |||
| Olivier Brandicourt | PCVX | Common Stock | Award | 87.6% | 2,194 | 4,699 | 15 Jun 2026 | Direct | ||
| Olivier Brandicourt | PCVX | Stock Option (right to buy) | Award | 11,034 | 11,034 | 15 Jun 2026 | Direct | |||
| John Furey | PCVX | Common Stock | Award | 74.5% | 2,265 | 5,306 | 15 Jun 2026 | Direct | ||
| John Furey | PCVX | Stock Option (right to buy) | Award | 11,389 | 11,389 | 15 Jun 2026 | Direct | |||
| Jacks Lee | PCVX | Common Stock | Award | 49.3% | 2,265 | 6,856 | 15 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.